Scientific deep-dive

Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review

TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
15 min read·15 citations

Frequently Asked Questions

Across the TRIUMPH-1 pivotal phase 3 trial (2,339 randomized adults, 80-week primary endpoint), the most common adverse events at the 12 mg dose were gastrointestinal: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, and vomiting 25.3%, vs much lower rates on placebo. The other standout signal is dysesthesia (tingling, burning, pins-and-needles, skin sensitivity): 12.5% on retatrutide 12 mg vs 0.9% on placebo. It is not unique to retatrutide. The Wegovy label reports dysesthesia in 22% of patients on semaglutide 7.2 mg and 6% on 2.4 mg vs 0% on placebo, but it is much more frequent than in the tirzepatide (Zepbound, 0.2-0.4%) or orforglipron (Foundayo, up to 1%) programs.
Dysesthesia is an abnormal sensory experience, typically described as tingling, burning, pins-and-needles, numbness, or itching that does not match a clear external stimulus. In TRIUMPH-1, dysesthesia was reported in 12.5% of patients on retatrutide 12 mg vs 0.9% on placebo — a roughly 14-fold imbalance. The mechanism is not yet established. A contribution from the glucagon-receptor arm of retatrutide's triple agonism has been proposed, but high-dose semaglutide, a pure GLP-1 agonist, also produces it (22% at 7.2 mg), and the Wegovy label says the rate rises with dose and drug levels in the blood. Confirmation requires post-marketing surveillance and dedicated mechanistic study.
On gastrointestinal events, retatrutide 12 mg in TRIUMPH-1 runs close to Wegovy and above Zepbound: nausea 42.4% (vs Wegovy STEP-1 44.1% and Zepbound 15 mg in SURMOUNT-1 31.9%); diarrhea 32.0% (vs 31.5% and 23.7%); constipation 26.1% (vs 23.4% and 12.7%); vomiting 25.3% (vs 24.6% and 12.9%). The Wegovy and Zepbound figures are from the trials' posted ClinicalTrials.gov results, which count events through week 75 for STEP-1 and week 193 for SURMOUNT-1. Treatment-emergent adverse-event discontinuation at retatrutide 12 mg was 11.3% (vs 4.9% placebo), above the 4.3-7.1% range for Zepbound SURMOUNT-1. The STEP-1 abstract reports only discontinuation for gastrointestinal events (4.5% on Wegovy vs 0.8% on placebo). The dysesthesia rate of 12.5% stands out; among approved drugs only high-dose semaglutide (22% at 7.2 mg per the Wegovy label) reports a comparable rate.
Not as of October 2026 — still investigational, and no application has been filed with the FDA yet. Eli Lilly reported the TRIUMPH-1 pivotal phase 3 results in May 2026 (published in NEJM in September 2026), and on July 23, 2026 reported positive topline results from TRIUMPH-2 (type 2 diabetes plus obesity/overweight; published in The Lancet in September 2026 with -18.8% mean weight loss at 12 mg on the intention-to-treat analysis, vs up to 20.8% in Lilly's efficacy-estimand topline) and TRIUMPH-3 (severe obesity with established cardiovascular disease; up to 22.6% weight loss at 80 weeks in the topline release). With all three pivotal trials now positive, Lilly says it is completing the Chemistry, Manufacturing, and Controls (CMC) data package and plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 — later than some earlier estimates, because Lilly said it needs more time on manufacturing data. The brand name has not yet been announced. Based on a Q1 2027 filing and typical FDA review timelines, approval is unlikely before late 2027 or 2028.
Discontinuation due to adverse events was 11.3% in the retatrutide 12 mg arm vs 4.9% in the placebo arm — a 6.4 percentage-point absolute increase. By comparison, STEP-1 reported that 4.5% of participants on semaglutide 2.4 mg vs 0.8% on placebo stopped because of gastrointestinal events, and SURMOUNT-1 reported 4.3-7.1% across tirzepatide 5/10/15 mg arms vs 2.6% placebo. Retatrutide produces the largest mean weight loss in the GLP-1 class to date (-25.0% at 80 weeks on 12 mg in the published intention-to-treat analysis; Lilly's press release cited -28.3% under the efficacy estimand, which estimates the effect had everyone stayed on treatment) but at a meaningfully higher discontinuation cost, reflecting both the higher GI rates and the dysesthesia signal.
Mostly, yes. In TRIUMPH-1 the 4 mg dose produced -17.6% mean weight loss at 80 weeks (intention-to-treat) with a much milder profile than 12 mg: nausea 28.6% vs 42.4%, vomiting 10.6% vs 25.3%, dysesthesia 5.1% vs 12.5%, and AE discontinuation 4.1% (below placebo's 4.9%) vs 11.3%. The 9 mg dose produced -23.7% with rates close to 12 mg (dysesthesia 12.3%, diarrhea 34.1%). The AE rates come from Lilly's topline release; the weight figures from the NEJM paper. Patients and prescribers may face a deliberate trade-off between weight-loss magnitude and tolerability, similar to the dose-titration decisions already familiar with tirzepatide. The 12 mg arm produced the largest weight loss but also the highest dysesthesia rate, the highest GI rates, and the highest discontinuation rate.
Rare adverse events — including thyroid C-cell tumor signals, severe pancreatitis, gallbladder events at population scale, and any retatrutide-specific signals that did not surface in a 2,339-patient phase 3 — typically only become visible in post-marketing surveillance after years of broad real-world use. TRIUMPH-2 (type 2 diabetes, published in The Lancet in September 2026) adds another 1,152 participants of safety data, and the TRIUMPH-3 manuscript (adults with established cardiovascular disease) is still pending; neither is large or long enough to rule out rare events. The FDA-approved label, once issued, will carry the formal warnings and precautions section; until then, the trial-level data are the best available evidence.
Long-term data on retatrutide-associated dysesthesia are not yet available. Lilly's TRIUMPH-1 release said dysesthesia events were generally mild to moderate, that the majority resolved during treatment, and that most participants continued taking retatrutide. What happens after stopping the drug, and whether any cases persist, has not been reported in detail and will need confirmation from the full trial data and post-marketing surveillance. Patients experiencing dysesthesia should report it to their prescribing clinician for the FDA Adverse Event Reporting System (FAERS) record once retatrutide is approved.
Orforglipron (Foundayo) is a pure GLP-1 monoagonist (oral small molecule); retatrutide is a GLP-1/GIP/glucagon triple agonist (injectable peptide). In ATTAIN-1, Foundayo 36 mg produced -11.2% TBWL with AE discontinuation 5.3-10.3% (vs 2.7% placebo) and a low dysesthesia rate (up to 1% vs 0.1% on placebo in the Foundayo label). In TRIUMPH-1, retatrutide 12 mg produced -25.0% mean weight loss (intention-to-treat, NEJM) with AE discontinuation 11.3% (vs 4.9% placebo) AND a 12.5% dysesthesia rate. In cross-trial comparison retatrutide produces roughly 2.2x the weight loss but carries higher GI rates, a higher discontinuation rate, and a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide.
Weight regain is the expected outcome after stopping retatrutide, based on the consistent pattern seen across every GLP-1 receptor agonist studied to date. The appetite-suppressing, satiety-enhancing, and energy-expenditure-modifying effects of GLP-1, GIP, and glucagon receptor agonism all depend on continued drug exposure - when the drug clears, the underlying physiology of obesity reasserts itself. The closest analog data comes from STEP-4 (semaglutide discontinuation), where patients who stopped after completing a 20-week titration regained roughly two-thirds of their lost weight within one year, and from SURMOUNT-4 (tirzepatide discontinuation), where roughly half of the lost weight came back within a year. No published withdrawal trial exists for retatrutide specifically, since it is not yet FDA-approved and the TRIUMPH program did not include a randomized withdrawal arm that has read out. Given that retatrutide produces the largest mean weight loss in the class (-25.0 percent at 80 weeks at the 12 mg dose in the published intention-to-treat analysis), the magnitude of potential regain after stopping may be correspondingly large. As with Wegovy and Zepbound, clinicians and patients should plan stopping retatrutide deliberately - considering continuation, dose reduction, or transition to another agent - rather than treating it as a finite course of treatment.
Retatrutide is not yet FDA-approved as of October 2026, so no official prescribing information label has been issued and the formal contraindication list is not yet final. Based on its mechanism as a triple GLP-1/GIP/glucagon receptor agonist and the precedent set by the approved class, expected absolute contraindications include: a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to the rodent thyroid C-cell tumor signal that carries a boxed warning across every approved GLP-1 receptor agonist; and known serious hypersensitivity to the drug. Pregnancy is not listed as a contraindication on current GLP-1 labels, but they warn that the drugs may cause fetal harm and advise stopping once a pregnancy is recognized, so the same caution would be expected. The dysesthesia signal from TRIUMPH-1 (12.5 percent on 12 mg vs 0.9 percent on placebo) may lead to additional cautions or monitoring requirements for patients with pre-existing peripheral neuropathy or sensory disorders, but those specifics await the FDA-approved label. Standard class-level cautions - pancreatitis history, concomitant use of insulin or sulfonylureas (hypoglycemia risk), severe gastroparesis - will also likely appear in the label. Compounded retatrutide is not legal in the US under current FDA policy and should not be used by any patient regardless of profile.

The honest answer:

Retatrutide (Eli Lilly LY3437943) is an investigational once-weekly subcutaneous triple agonist of GLP-1, GIP, and glucagon receptors. The TRIUMPH-1 pivotal phase 3 trial (n=2,339, 80-week primary endpoint, 104-week extension) was announced by Lilly in May 2026[1] and published in the New England Journal of Medicine on September 29, 2026[9]. The per-arm adverse-event rates below come from Lilly’s topline release. The retatrutide adverse-event profile is class-typical on the gastrointestinal axis — plus one standout signal . At the 12 mg dose: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, and vomiting 25.3%[1] — close to Wegovy STEP-1[12] and above Zepbound SURMOUNT-1[11]. The standout signal is dysesthesia at 12.5% on retatrutide 12 mg vs 0.9% on placebo[1], roughly a 14-fold imbalance. It is not unique to retatrutide: the Wegovy label reports dysesthesia in 22% of patients on semaglutide 7.2 mg and 6% on 2.4 mg vs 0% on placebo[13], but it is much more frequent than with tirzepatide (0.2–0.4%)[14] or orforglipron (up to 1%)[15]. Treatment-emergent adverse-event discontinuation at the 12 mg arm was 11.3% vs 4.9% placebo[1], above the SURMOUNT-1 Zepbound range (4.3-7.1%)[6]. Retatrutide produced the largest weight loss in any GLP-1-class trial to date (−25.0% at 80 wk on 12 mg in the published intention-to-treat analysis[9]; Lilly’s release cited −28.3% under the efficacy estimand, which estimates the effect had everyone stayed on treatment[1]), but the tolerability ledger carries a frequent sensory-symptom signal that prescribers and patients will need to weigh. All three TRIUMPH pivotal trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3) have now reported positive topline results[1][8], and TRIUMPH-1 and TRIUMPH-2 are now peer-reviewed[9][10], but retatrutide is still not yet FDA-approved and the brand name has not been announced. Lilly plans to file a Biologics License Application (BLA) in Q1 2027.

The honest short answer

  • Retatrutide’s GI adverse events follow the familiar GLP-1 pattern, at the high end of the class. At 12 mg in TRIUMPH-1: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3%[1]. Nausea and diarrhea sit close to Wegovy STEP-1 (Wilding 2021 NEJM[5]; posted ClinicalTrials.gov results[12]); constipation and vomiting run above both Wegovy and Zepbound 15 mg in SURMOUNT-1 (posted ClinicalTrials.gov results, which count events through week 193)[11].
  • Dysesthesia is the standout retatrutide signal. 12.5% on retatrutide 12 mg vs 0.9% on placebo, a ~14-fold imbalance. It also occurs with high-dose semaglutide (22% at 7.2 mg and 6% at 2.4 mg vs 0% on placebo in the Wegovy label[13]) but is rare with tirzepatide (0.2–0.4%)[14] and orforglipron (up to 1%)[15]. A glucagon-receptor contribution has been proposed but is not confirmed.
  • Discontinuation due to adverse events at 12 mg was 11.3% vs 4.9% placebo. Higher than the SURMOUNT-1 Zepbound range (4.3-7.1%)[6]; STEP-1 reported only discontinuation for gastrointestinal events on Wegovy (4.5% vs 0.8%)[5]. The trade-off: largest weight loss in the class, at a meaningfully higher tolerability cost.
  • The AE profile is dose-dependent. Retatrutide 4 mg (−17.6% at 80 wk, ITT) is substantially better tolerated than 12 mg (−25.0%)[9]: dysesthesia 5.1% vs 12.5% and AE discontinuation 4.1% vs 11.3%[1]. The 9 mg arm (−23.7%) has AE rates close to 12 mg. Prescribers and patients may negotiate the dose-vs-tolerability trade-off similarly to how tirzepatide 5/10/15 mg decisions are made today.
  • Retatrutide is NOT yet FDA-approved as of October 2026. TRIUMPH-1 was published in the New England Journal of Medicine[9] and TRIUMPH-2 (type 2 diabetes) in The Lancet[10] on September 29, 2026. TRIUMPH-3 (established cardiovascular disease, up to 22.6% weight loss at 80 wk in Lilly’s July 23, 2026 topline release[8]) is not yet published. With all five phase 3 trials in the program now positive, Lilly plans to file a BLA in Q1 2027.
  • Rare adverse events typically emerge in post-marketing surveillance, not in 2,339-patient pivotal trials. Until the FDA-approved label is issued and FAERS data accumulates, the trial-level safety data are the best available evidence — but they are not the last word.

What TRIUMPH-1 actually measured

TRIUMPH-1 (ClinicalTrials.gov NCT05929066)[2] is the pivotal phase 3 randomized, double-blind, placebo-controlled trial of retatrutide in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity and without diabetes. 2,339 participants were randomized to weekly subcutaneous retatrutide at one of three maintenance doses (4 mg, 9 mg, or 12 mg) or placebo, escalated from a 2 mg starting dose stepping up every 4 weeks (2 → 4 → 6 → 9 → 12 mg) until the assigned maintenance dose was reached. The primary endpoint was percent change in body weight from baseline to week 80; a 104-week extension reported continued weight loss in the BMI ≥35 subgroup.

The headline efficacy at 80 weeks, from the published NEJM paper (treatment-regimen, or intention-to-treat, estimand): retatrutide 12 mg produced −25.0% mean body-weight change vs −3.9% on placebo; 9 mg produced −23.7% and 4 mg −17.6%[9]. Lilly’s May 2026 release headlined the efficacy estimand, which estimates the effect had all participants remained on treatment: −28.3% (about 70.3 pounds from a 248.5-pound average baseline), −25.9%, and −19.0% vs −2.2% on placebo[1]. In the 104-week extension for participants with BMI ≥35, the 12 mg arm reached −30.3% (efficacy estimand; −29.9% treatment-regimen)[1].

For comparison: Wegovy STEP-1 (Wilding 2021 NEJM)[5] reported −14.9% TBWL at 68 weeks on semaglutide 2.4 mg weekly. Zepbound SURMOUNT-1 (Jastreboff 2022 NEJM)[6] reported −20.9% TBWL at 72 weeks on tirzepatide 15 mg weekly. Foundayo ATTAIN-1 (Wharton 2025 NEJM)[7] reported −11.2% TBWL at 72 weeks on orforglipron 36 mg oral daily. Those three figures use the same treatment-regimen estimand as the published TRIUMPH-1 −25.0%, so in cross-trial indirect comparison retatrutide 12 mg produced roughly 1.2x the weight loss of tirzepatide 15 mg, 1.7x that of semaglutide 2.4 mg, and 2.2x that of orforglipron 36 mg.

Which TRIUMPH-1 numbers this article uses. The TRIUMPH-1 manuscript was published in the New England Journal of Medicine on September 29, 2026 (Jastreboff 2026)[9]; its weight analysis uses the treatment-regimen estimand, which counts everyone randomized whether or not they stayed on the drug. Lilly’s May 21, 2026 release[1] led with the efficacy estimand, which runs higher. This article leads with the published figures. The per-arm adverse-event and discontinuation rates still come from Lilly’s release, because the NEJM abstract states only that gastrointestinal events were the most common. TRIUMPH-2 (adults with type 2 diabetes) was published in The Lancet the same day[10]; the TRIUMPH-3 manuscript is still pending. The TRIUMPH program design paper (Giblin 2026 Diabetes Obes Metab)[3] and the phase 2 lipid and metabolite analysis (Pearson 2026 JCEM)[4] are also published.

GI adverse-event rates — nausea, diarrhea, constipation, vomiting

The gastrointestinal adverse-event pattern in TRIUMPH-1 at the 12 mg dose[1]:

  • Nausea: 42.4% on retatrutide 12 mg vs 14.8% on placebo. Class-typical magnitude. Mostly mild to moderate; concentrated during dose escalation; usually resolves or attenuates after the patient has spent 2 to 4 weeks at the dose step.
  • Diarrhea: 32.0% on retatrutide 12 mg vs 13.5% on placebo. Also class-typical. The combined GLP-1 + GIP + glucagon agonism slows gastric emptying and alters small-bowel motility; diarrhea is the predictable counterpart to the slowed-upper- GI nausea signal.
  • Constipation: 26.1% on retatrutide 12 mg vs 10.9% on placebo. The slowed gastric emptying and reduced food intake combine to produce constipation in roughly one-quarter of patients at the 12 mg maintenance dose — consistent with the Zepbound and Wegovy patterns.
  • Vomiting: 25.3% on retatrutide 12 mg vs 4.8% on placebo. Roughly double the Zepbound 15 mg SURMOUNT-1 rate (12.9%)[11] and roughly equal to the Wegovy STEP-1 24.6%[12]. The placebo-arm vomiting rate is notably low (4.8%), giving a ~20 percentage-point absolute imbalance.
  • Treatment-emergent AE discontinuation at 12 mg: 11.3% vs 4.9% placebo. This is the cleanest integrated tolerability metric because it captures patients who stopped therapy for any AE-related reason. The 6.4 percentage-point absolute increase is the headline tolerability cost.

The clinical interpretation is the standard GLP-1-class one: GI symptoms are the dominant tolerability challenge, are largely time-limited per dose step, and are usually manageable with the same strategies that work for injectable monoagonists and dual agonists — smaller meals, avoiding very rich or greasy foods, eating slowly, stopping at the first sign of fullness, staying hydrated, and slowing the titration if any particular dose step is intolerable. For patient-facing GI management advice see the GLP-1 side effects Q&A and the interactive GLP-1 side-effect timeline tool.

Dysesthesia — retatrutide's standout signal

Dysesthesia is the standout adverse-event signal in the retatrutide pivotal data. The reported rate at TRIUMPH-1 12 mg is 12.5% vs 0.9% on placebo[1] — an absolute increase of 11.6 percentage points and roughly a 14-fold relative imbalance. It is not unique to retatrutide: the Wegovy label reports dysesthesia in 22% of patients on semaglutide 7.2 mg and 6% on 2.4 mg vs 0% on placebo, and says the incidence rose with dose and drug levels in the blood[13]. It is much rarer with tirzepatide (0.2–0.4% vs 0.1% on placebo)[14] and orforglipron (0.3–1% vs 0.1%)[15].

What is dysesthesia clinically? Dysesthesia is an abnormal sensory experience — typically tingling, burning, pins-and-needles, numbness, itching, or a pricking sensation — that does not correspond to a clear external stimulus. It is distinct from paresthesia (which is the same sensory category but commonly transient and benign, like a foot “falling asleep”) and from neuropathy (which implies established structural nerve damage). Lilly’s TRIUMPH-1 release describes the dysesthesia events as generally mild to moderate and says the majority resolved during treatment and most participants kept taking retatrutide[1]. It does not describe where the symptoms occurred (peripheral, oral, scalp, etc.) or what happened after discontinuation; the FDA-approved label, once issued, will carry the formal description.

Why is dysesthesia so frequent with retatrutide? One hypothesis is that the glucagon-receptor arm of retatrutide’s triple agonism contributes. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors; tirzepatide is a dual GIP+GLP-1 agonist (no glucagon arm) and orforglipron is a pure GLP-1 monoagonist, and both show low rates. But semaglutide, also a pure GLP-1 monoagonist, produces dysesthesia at high doses, and the Wegovy label ties the rate to dose and drug levels in the blood[13], so a glucagon-specific explanation is not required. The causal mechanism is not established; it remains a question for dedicated mechanistic study and post-marketing surveillance.

Is it dose-related? Partly. In TRIUMPH-1, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants on 4, 9, and 12 mg vs 0.9% on placebo[1] — a clear step up from 4 mg to 9 mg, then roughly flat. In TRIUMPH-2 (adults with type 2 diabetes) the rates were lower: 4%, 6%, and 7% vs 1% on placebo[10].

Practical implication for prescribers. Dysesthesia is an adverse-event category that prescribers will need to elicit actively at follow-up visits once retatrutide is approved — patients may not volunteer sensory symptoms unless asked, particularly because tingling or burning sensations are often dismissed as nonspecific. Pre-treatment counseling should include the symptom category and the instruction to report new sensory symptoms. Discontinuation criteria for dysesthesia will be specified in the FDA-approved label.

Practical implication for patients. If you experience new, persistent tingling, burning, pins-and-needles, numbness, or unexplained itching while on retatrutide (post-approval), report it to your prescribing clinician. The symptom is on the radar of the trial investigators; it is labeled and tracked; it is not a mystery symptom.

Discontinuation rate — the integrated tolerability metric

Treatment-emergent adverse-event discontinuation is the cleanest cross-trial tolerability metric because it integrates symptom severity, persistence, and patient-level decision-making across the full trial duration. In TRIUMPH-1 at the 12 mg dose, AE discontinuation was 11.3% vs 4.9% placebo[1] — an absolute increase of 6.4 percentage points.

Cross-trial context:

  • STEP-1 (Wegovy semaglutide 2.4 mg, 68 wk): discontinuation for gastrointestinal events 4.5% vs 0.8% placebo; the abstract does not give the all-cause adverse-event figure[5].
  • SURMOUNT-1 (Zepbound tirzepatide, 72 wk): AE discontinuation 4.3 to 7.1% across 5/10/15 mg arms vs 2.6% placebo (absolute increase 1.7 to 4.5 pp)[6].
  • ATTAIN-1 (Foundayo orforglipron, 72 wk): AE discontinuation 5.3 to 10.3% across 6/12/36 mg arms vs 2.7% placebo (absolute increase 2.6 to 7.6 pp)[7].
  • TRIUMPH-1 (retatrutide 12 mg, 80 wk): AE discontinuation 11.3% vs 4.9% placebo (absolute increase 6.4 pp)[1].

Retatrutide’s 11.3% discontinuation rate is above every all-cause figure in this list. The interpretation depends on the denominator the prescriber uses. Per-patient-on-therapy, approximately 9 of 10 retatrutide 12 mg patients tolerated the drug well enough to remain on it through 80 weeks. Per unit of weight loss, retatrutide produced −25.0% at the 12 mg dose in the published intention-to-treat analysis[9] — meaning the discontinuation cost was 11.3% to access roughly 1.2x the weight loss of tirzepatide 15 mg or 1.7x that of semaglutide 2.4 mg. Whether that trade-off is acceptable will be a patient- and-prescriber-specific decision once the drug is approved.

Class comparison — retatrutide vs tirzepatide vs semaglutide vs orforglipron

Side-by-side adverse-event rates at the labeled high-dose arms of the four molecules (cross-trial indirect comparison; the Wegovy and Zepbound GI rates come from the trials’ posted ClinicalTrials.gov results, which count events through week 75 for STEP-1 and week 193 for SURMOUNT-1 rather than the primary endpoint):

  • Nausea: retatrutide 12 mg 42.4%[1], Wegovy semaglutide 2.4 mg 44.1%[12], Zepbound tirzepatide 15 mg 31.9%[11], Foundayo orforglipron 36 mg in the qualitative GI-dominant range from ATTAIN-1[7].
  • Diarrhea: retatrutide 12 mg 32.0%, Wegovy 31.5%, Zepbound 23.7%. Comparable across the class.
  • Constipation: retatrutide 12 mg 26.1%, Wegovy 23.4%, Zepbound 12.7%. Retatrutide marginally higher than Wegovy and about double Zepbound.
  • Vomiting: retatrutide 12 mg 25.3%, Wegovy 24.6%, Zepbound 12.9%. Retatrutide and Wegovy approximately equal; both ~2x Zepbound.
  • AE discontinuation: retatrutide 12 mg 11.3% vs 4.9% placebo, Zepbound 4.3-7.1% vs 2.6% placebo, Foundayo 5.3-10.3% vs 2.7% placebo; Wegovy STEP-1 reported only gastrointestinal-event discontinuation (4.5% vs 0.8% placebo). Retatrutide is the highest.
  • Dysesthesia: retatrutide 12 mg 12.5% vs 0.9% placebo. Also reported with high-dose semaglutide (22% at 7.2 mg, 6% at 2.4 mg in the Wegovy label) but rare with tirzepatide and orforglipron (about 1% or less).
  • Magnitude of weight loss: retatrutide 12 mg −25.0% at 80 wk (intention-to-treat; −28.3% under Lilly’s efficacy estimand)[9][1], Zepbound 15 mg −20.9% at 72 wk[6], Wegovy 2.4 mg −14.9% at 68 wk[5], Foundayo 36 mg −11.2% at 72 wk[7].

The taxonomy is clean. Retatrutide produces the largest mean weight loss in the class, with a GI profile at the high end of the class (close to Wegovy, above Zepbound), plus a frequent dysesthesia signal and a meaningfully higher AE discontinuation rate. For the full pipeline landscape including survodutide, MariTide (maridebart cafraglutide), and ecnoglutide, see our GLP-1 pipeline review.

Magnitude comparison

Selected adverse-event rates and treatment-emergent discontinuation across the four highest-dose pivotal-trial arms: retatrutide 12 mg (TRIUMPH-1, n=2,339, 80 wk), Wegovy semaglutide 2.4 mg (STEP-1, n=1,961, 68 wk; GI rates from posted ClinicalTrials.gov results, which run through week 75), Zepbound tirzepatide 15 mg (SURMOUNT-1, n=2,539; GI rates from posted ClinicalTrials.gov results, which run through week 193), and Foundayo orforglipron 36 mg (ATTAIN-1, n=3,127, 72 wk). Dysesthesia is also reported with semaglutide (6% at 2.4 mg, 22% at 7.2 mg per the Wegovy label) but is rare with tirzepatide.[1][5][6][7][11][12]

  • Nausea — retatrutide 12 mg (TRIUMPH-1)42.4 %
    vs 14.8% placebo
  • Nausea — Wegovy 2.4 mg (STEP-1)44.1 %
    vs 17.4% placebo
  • Nausea — Zepbound 15 mg (SURMOUNT-1)31.9 %
    vs 9.8% placebo
  • Diarrhea — retatrutide 12 mg (TRIUMPH-1)32.0 %
    vs 13.5% placebo
  • Diarrhea — Zepbound 15 mg (SURMOUNT-1)23.7 %
    vs 7.9% placebo
  • Vomiting — retatrutide 12 mg (TRIUMPH-1)25.3 %
    vs 4.8% placebo
  • Vomiting — Zepbound 15 mg (SURMOUNT-1)12.9 %
    vs 1.9% placebo
  • Constipation — retatrutide 12 mg (TRIUMPH-1)26.1 %
    vs 10.9% placebo
  • Dysesthesia — retatrutide 12 mg (TRIUMPH-1)12.5 %
    vs 0.9% placebo; Wegovy label: 6% at 2.4 mg, 22% at 7.2 mg; Zepbound 0.2–0.4%
  • AE discontinuation — retatrutide 12 mg (TRIUMPH-1)11.3 %
    vs 4.9% placebo — highest in class
  • GI-event discontinuation — Wegovy 2.4 mg (STEP-1)4.5 %
    vs 0.8% placebo; gastrointestinal events only
  • AE discontinuation — Foundayo 36 mg range (ATTAIN-1)10.3 %
    5.3-10.3% dose-dependent vs 2.7% placebo
Selected adverse-event rates and treatment-emergent discontinuation across the four highest-dose pivotal-trial arms: retatrutide 12 mg (TRIUMPH-1, n=2,339, 80 wk), Wegovy semaglutide 2.4 mg (STEP-1, n=1,961, 68 wk; GI rates from posted ClinicalTrials.gov results, which run through week 75), Zepbound tirzepatide 15 mg (SURMOUNT-1, n=2,539; GI rates from posted ClinicalTrials.gov results, which run through week 193), and Foundayo orforglipron 36 mg (ATTAIN-1, n=3,127, 72 wk). Dysesthesia is also reported with semaglutide (6% at 2.4 mg, 22% at 7.2 mg per the Wegovy label) but is rare with tirzepatide.

Dose-response — AE rates at 4 mg vs 9 mg vs 12 mg

TRIUMPH-1 tested three maintenance doses (4 mg, 9 mg, 12 mg) and reported both efficacy and tolerability across the dose range[1][9]. The weight-loss gradient at 80 weeks (published intention-to-treat figures, with Lilly’s efficacy-estimand figures in parentheses):

  • Retatrutide 4 mg: −17.6% (−19.0%). A few points below Zepbound 15 mg (−20.9% in SURMOUNT-1)[6], with only one dose-escalation step.
  • Retatrutide 9 mg: −23.7% (−25.9%). Exceeds Zepbound 15 mg by ~3 percentage points.
  • Retatrutide 12 mg: −25.0% (−28.3%); −29.9% (−30.3%) at 104 wk in the BMI ≥35 extension — the largest mean weight loss in any GLP-1-class pivotal trial reported to date.

The AE rates mostly rise with dose. Per Lilly’s release (4 / 9 / 12 mg vs placebo): nausea 28.6% / 38.4% / 42.4% vs 14.8%; diarrhea 25.2% / 34.1% / 32.0% vs 13.5%; constipation 23.8% / 25.9% / 26.1% vs 10.9%; vomiting 10.6% / 22.8% / 25.3% vs 4.8%; dysesthesia 5.1% / 12.3% / 12.5% vs 0.9%; AE discontinuation 4.1% / 6.9% / 11.3% vs 4.9%[1]. The biggest jump is between 4 mg and 9 mg; diarrhea actually peaked at 9 mg. The 4 mg arm is the most tolerable maintenance dose, with AE discontinuation no higher than placebo — at the cost of giving up roughly 30% of the weight-loss magnitude available at 12 mg.

Clinical implication. Once retatrutide is FDA-approved, prescribers will likely make explicit dose-vs- tolerability trade-off decisions, similar to the existing tirzepatide 5/10/15 mg titration decisions but with a wider range. A patient who tolerates the 4 mg arm well but does not need maximum-magnitude weight loss may reasonably stay at 4 mg for maintenance. A patient who needs maximum-magnitude weight loss and accepts the higher AE burden can titrate to 12 mg. A patient who tolerates 9 mg may not need or want to push to 12 mg: the published difference between the two doses was only 1.3 percentage points (2.4 under the efficacy estimand), while AE discontinuation rose from 6.9% to 11.3%.

What we do not yet know about retatrutide safety

The TRIUMPH-1 readout is a 2,339-patient pivotal trial with an 80-week primary endpoint and a 104-week extension. That is substantial but does not exhaust the safety question. Several categories of safety information are not yet available:

  • Rare adverse events. Events that occur at rates below approximately 1 in 1,000 patient-years typically do not surface in pivotal trials of this size. Thyroid C-cell tumor signals, severe pancreatitis at population scale, and other rare-but-serious adverse events will only become visible in post-marketing surveillance via the FDA Adverse Event Reporting System (FAERS) and post-approval observational studies.
  • Dysesthesia mechanism, distribution, severity, and reversibility. Lilly reports the events as mostly mild to moderate and mostly resolving during treatment[1]; the post-approval FDA label will specify management and discontinuation criteria. Whether dysesthesia attenuates or resolves after discontinuation, whether it can transition to a structural neuropathy with sustained exposure, and whether it is reproducible with dose re-challenge are all currently unknown.
  • Long-term cardiovascular safety. TRIUMPH-3, a weight-management trial in adults with severe obesity (BMI ≥35) and established cardiovascular disease (weight endpoint, not a hard-outcomes trial), reported up to 22.6% weight loss at 80 weeks on July 23, 2026[8]. Lilly’s release also gave AE discontinuation of 9.8% (9 mg) and 13.5% (12 mg) vs 4.8% on placebo, and pre-specified cardiovascular-event analyses that were inconclusive: fewer events than anticipated occurred in both arms, and the hazard ratios for pooled retatrutide vs placebo were 0.82 for MACE-5 (95% CI 0.55–1.22) and 1.12 for MACE-3 (95% CI 0.64–1.96)[8]. Neither shows benefit or harm. The dedicated outcomes trial (TRIUMPH-Outcomes) is still running, and the TRIUMPH-3 manuscript is not yet published.
  • Adverse events in the type 2 diabetes population. TRIUMPH-2 (n=1,152, published in The Lancet) reported diarrhea in 27% / 34% / 34% and nausea in 14% / 21% / 28% on 4 / 9 / 12 mg vs 13% and 8% on placebo, plus more hypotension (up to 6% vs <1%) and dysesthesia (up to 7% vs 1%); discontinuation for adverse events or death was 4% / 12% / 8% vs 5%[10]. The abstract does not break out hypoglycemia, so the risk with background insulin or sulfonylureas still needs the full paper and, eventually, the label.
  • The FDA-approved label. The boxed warning (almost certainly the GLP-1-class thyroid C-cell tumor warning), the formal warnings and precautions section, the dosing instructions, and the contraindications will be finalized in the FDA-approved label, which has not yet been issued. Until then, the trial-level data are the best available evidence but not the regulatory authority.
  • Real-world tolerability in clinical practice. Trial populations are pre-screened for adherence likelihood and exclude many comorbidities. Real-world tolerability typically tracks somewhat worse than trial tolerability, as patients on multiple concomitant medications, with broader comorbidity profiles, and without trial-grade titration support encounter the drug.

Practical implications for prescribers and patients

Retatrutide is not yet FDA-approved, so the immediate practical implication is that no prescription can be written for it through legal US channels today. Compounded retatrutide is not legal in the US — retatrutide has no USP/NF monograph, is not on the FDA 503B bulks list, and is not on the FDA shortage list. The FDA has issued multiple Warning Letters in 2025 to compounders distributing retatrutide commercially. See our retatrutide approval and access timeline and the broader retatrutide triple agonist evidence review for the regulatory boundary and the published phase 2 data.

Once retatrutide is approved (Lilly plans to file its BLA in Q1 2027; FDA action would follow its standard review clock from there), the practical clinical considerations:

  • Counsel patients pre-treatment that nausea, diarrhea, constipation, and vomiting are expected, especially during the 16-week titration schedule (2 → 4 → 6 → 9 → 12 mg every 4 weeks). The same patient-management strategies that work for Wegovy and Zepbound translate.
  • Counsel patients pre-treatment about the dysesthesia signal. Patients should know that tingling, burning, pins-and-needles, or numbness should be reported promptly. It is far more common than on Zepbound or standard-dose Wegovy, so many patients will not have heard of it.
  • Plan the dose-vs-tolerability trade-off explicitly. The 12 mg dose produces the largest weight loss but the highest AE burden. The 4 mg dose is well-tolerated but gives up roughly one-third of the magnitude available at 12 mg. The 9 mg dose offers intermediate weight loss with intermediate AE rates.
  • Monitor renal function during titration. The GLP-1-class warning for acute kidney injury secondary to volume contraction from severe GI losses applies here too. Patients with chronic kidney disease, on diuretics, or with a history of dehydration require closer monitoring.
  • Coordinate with diabetes medications in the T2D subset. Hypoglycemia risk when retatrutide is combined with insulin or a sulfonylurea is the predictable class-typical concern, managed by downward titration of the background secretagogue or insulin. TRIUMPH-2 topline (July 2026) already confirms substantial glycemic benefit (up to 1.6% mean A1C reduction) alongside the weight loss[8].
  • Use the same off-ramp planning as for Wegovy and Zepbound. Weight regain after stopping is the expected pattern for every GLP-1 receptor agonist. The STEP-4 data on semaglutide discontinuation and the SURMOUNT-4 data on tirzepatide discontinuation both showed substantial weight regain after treatment cessation. Plan continuation, dose tapering, or transition to a different molecule deliberately with the patient.

For patients evaluating where retatrutide may eventually fit in their treatment plan, the comparison-tool walkthrough for the closest peer drug is the Foundayo side effects comprehensive evidence review — orforglipron is the most recently approved GLP-1 for weight management and the most relevant near-term comparator for cost, access, and route-of-administration questions. The retatrutide trial data establish that the molecule will be more efficacious than Foundayo and roughly 1.2x the mean weight loss of Zepbound in cross-trial comparison, at the cost of a higher AE burden and the frequent dysesthesia signal.

Bottom line

Retatrutide’s TRIUMPH-1 pivotal phase 3 readout established two things at once. First, the molecule produces the largest mean weight loss in the GLP-1 receptor agonist class to date: −25.0% at 80 weeks on the 12 mg dose in the published intention-to-treat analysis[9] (−28.3% under Lilly’s efficacy estimand, and about 30% at 104 weeks in the BMI ≥35 extension[1]). Second, the adverse-event ledger carries a frequent dysesthesia signal (12.5% on 12 mg vs 0.9% on placebo; high-dose semaglutide shows a similar signal) on top of class-typical but slightly worse gastrointestinal rates and a higher treatment discontinuation rate (11.3%) than the established injectable comparators.

For patients evaluating retatrutide once it is FDA-approved, the question is not whether retatrutide is more efficacious than Wegovy[5], Zepbound[6], or Foundayo[7] — it clearly is, in cross-trial indirect comparison. The question is whether the additional weight-loss magnitude is worth the additional GI burden, the higher discontinuation rate, and the frequent dysesthesia signal. That is a patient-and-prescriber-specific call that will be informed by the FDA-approved label, the TRIUMPH-2 type 2 diabetes data (now published)[10], the TRIUMPH-3 data in people with cardiovascular disease (topline positive, up to 22.6% weight loss; manuscript pending)[8], and the post-marketing surveillance evidence that accumulates over years of broad use.

TRIUMPH-1 (New England Journal of Medicine) and TRIUMPH-2 (The Lancet) were published on September 29, 2026[9][10]; the TRIUMPH-3 manuscript is still pending. Lilly says it plans to submit a Biologics License Application to the FDA in Q1 2027. This article will be updated as each milestone lands. Until then, the trial-level safety and efficacy data summarized here are the best available evidence on retatrutide side effects.

Retatrutide is investigational and is not FDA-approved as of October 2026; no legal US prescription channel exists for the drug today. Compounded retatrutide is not legal in the US per FDA Warning Letters issued throughout 2025. Weight outcomes are from the TRIUMPH-1 NEJM paper (PMID 42814954) and TRIUMPH-2 Lancet paper (PMID 42810372); TRIUMPH-1 per-arm adverse-event rates are from Eli Lilly’s May 21, 2026 release. TRIUMPH-2 and TRIUMPH-3 topline results (July 23, 2026, Lilly investor release/PR Newswire) were verified live on 2026-08-02; the TRIUMPH-1 and TRIUMPH-2 papers and the May 21 release were re-verified live on 2026-10-16. This article will be updated when each peer-reviewed TRIUMPH manuscript lands and again when the FDA-approved label is issued.

Further reading

References

  1. 1.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results, May 21, 2026). PR Newswire (Lilly investor release). 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  2. 2.Eli Lilly and Company. A study of retatrutide (LY3437943) in participants with obesity or overweight (TRIUMPH-1). ClinicalTrials.gov NCT05929066. 2026. https://clinicaltrials.gov/study/NCT05929066
  3. 3.Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PMID: 41090431.
  4. 4.Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  5. 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  6. 6.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  7. 7.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  8. 8.Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2, TRIUMPH-3 topline results). PR Newswire (Lilly investor release). 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
  9. 9.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  10. 10.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  11. 11.Eli Lilly and Company. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities (SURMOUNT-1): posted adverse-event results. ClinicalTrials.gov NCT04184622. 2025. https://clinicaltrials.gov/study/NCT04184622?tab=results
  12. 12.Novo Nordisk A/S. Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1): posted adverse-event results. ClinicalTrials.gov NCT03548935. 2021. https://clinicaltrials.gov/study/NCT03548935?tab=results
  13. 13.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, §6.1 Adverse Reactions (dysesthesia). DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  14. 14.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, §6.1 Adverse Reactions (dysesthesia). DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  15. 15.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, §6.1 Adverse Reactions (dysesthesia). DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence

Retatrutide -25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs tirzepatide -20.9% at 15 mg / 72 wk (SURMOUNT-1), about 4 points on a cross-trial basis. Nausea, a dysesthesia signal, and discontinuation run higher, and retatrutide is not FDA-approved.

11 min read

Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding

Retatrutide is not FDA-approved. Lilly plans to file in the first quarter of 2027, so it will not be prescribable in 2026. TRIUMPH-1 showed up to 25.0% weight loss at 80 weeks, and it cannot legally be compounded under 503A or 503B.

12 min read

Retatrutide Before and After: What TRIUMPH-1 Actually Showed

TRIUMPH-1 (n=2,339; NEJM 2026) reported -25.0% mean weight loss at 80 weeks on retatrutide 12 mg (intention-to-treat; Lilly's press release cited -28.3% on-treatment). Honest framing of transformation magnitude, dose-response, and real-world expectations.

12 min read

Retatrutide TRIUMPH Phase 3: Latest Pipeline Update

In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.

11 min read

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)

Retatrutide (investigational) -25.0% TBWL at 12 mg / 80 wk in TRIUMPH-1 vs Wegovy (FDA-approved 2021) -14.9% at 68 wk in STEP-1, about 1.7x on a cross-trial basis. No head-to-head RCT. Wegovy has SELECT (20% MACE reduction); retatrutide's outcomes trial is ongoing.

12 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $289/4 wks

billed per 4 weeks

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →